Trial
NCT01604889
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Incyte Corporation
Collaborators
—
Condition
Melanoma
Intervention
Epacadostat
Why stopped
Further development of this compound with ipilimumab in the treatment of melanoma is no longer being pursued.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-21